

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of
The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): **October 15, 2021**

KNOW LABS, INC.

(Exact name of registrant as specified in its charter)

Nevada

(State of other jurisdiction
of incorporation)

000-30262

(Commission
File Number)

90-0273142

(IRS Employer
Identification No.)

500 Union Street, Suite 810

Seattle, Washington 98101

(Address of principal executive office)

(206) 903-1351

(Registrant's telephone number, including area code)

(Former name, former address and former fiscal year, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions see General Instruction A.2. below):

- ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act: None

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company. ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01 Regulation FD Disclosure.

On October 15, 2021, Know Labs, Inc. (the “Company”) made available an annual meeting presentation to its stockholders at its Annual Shareholder meeting.

The presentation is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information furnished in this Item 7.01 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section, nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended.

The Company is not undertaking to update this presentation. This report is not intended as a statement concerning the materiality of any information contained in the presentation.

A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.

Exhibit No.	Description
99.1	Know Labs Annual Shareholder meeting presentation dated October 15, 2021

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Registrant: **KNOW LABS, INC.**

October 15, 2021

By: s/s Ronald P. Erickson
Ronald P. Erickson
Chairman of the Board



Annual Shareholder Meeting

OTCQB: KNWN

1. Introductions
2. Vote Report
3. Business Update
4. Q&A

October 15, 2021

Disclaimers



Safe Harbor Statement

This document contains statements that constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements appear in a number of places in this release and include all statements that are not statements of historical fact regarding the intent, belief or current expectations of Know Labs, Inc., its directors or its officers with respect to, among other things: (i) financing plans; (ii) trends affecting its financial condition or results of operations; (iii) growth strategy and operating strategy; and (iv) performance of products. You can identify these statements by the use of the words "may," "will," "could," "should," "would," "plans," "expects," "anticipates," "continue," "estimate," "project," "intend," "likely," "forecast," "probable," "potential," and similar expressions and variations thereof are intended to identify forward-looking statements. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond Know Labs, Inc.'s ability to control, and actual results may differ materially from those projected in the forward-looking statements as a result of various factors. These risks and uncertainties also include such additional risk factors as are discussed in the Company's filings with the U.S. Securities and Exchange Commission, including its Annual Report on Form 10-K for the fiscal year ended September 30, 2020, Forms 10-Q and 8-K, and in other filings we make with the Securities and Exchange Commission from time to time. These documents are available on the SEC Filings section of the Investor Relations section of our website at www.knowlabs.co. The Company cautions readers not to place undue reliance upon any such forward-looking statements, which speak only as of the date made. The Company undertakes no obligation to update any forward-looking statement to reflect events or circumstances after the date on which such statement is made.

Notice of Non-Affiliation and Disclaimer

Dexcom G6® is a registered trademark of Dexcom, Inc. Freestyle® is a registered trademark of Abbott Laboratories, Inc. Accu-Chek® is a registered trademark of Roche Diabetes Care, Inc. Know Labs is not affiliated, associated, authorized, endorsed by, or in any way officially connected with Dexcom, Abbott Laboratories or Roche Diabetes Care, or any of its subsidiaries or its affiliates.

Our Vision



Transform medical diagnostics and launch first truly non-invasive FDA approved blood glucose monitoring device.




Offer medical-grade and affordable solutions for people with type 1 and type 2 diabetes, people with pre-diabetes, and people with no diabetes but interested in monitoring their blood glucose levels.



Following FDA clearance of the glucose monitoring devices, expand Bio-RFID™ to other potential medical diagnostic applications.

FY2021 Highlights



KnowU™ and UBand™

KNOW LABS' SOLUTIONS TO NON-INVASIVE GLUCOSE MONITORING

- Bio-RFID technology
- Completely non-invasive
- No finger sticks or needles
- No filaments, transmitters or other supplies
- Real-time readings
- Smartphone app
- Estimated cost <\$1K/year
(compared to \$1 to >\$5k for current alternative products)



KnowU
On-Demand and On-the-Go




UBand
Continuous and Wearable



Bio-RFID vs. FDA-Cleared Glucose Monitoring Devices




MARD [%] = Mean Absolute Relative Difference, Bio-RFID vs. Reference Device; lower is better





Bio-RFID vs. Accu-Chek Fingerstick


AUG-11, 2021; KNOW LABS R&D LABORATORY





Bio-RFID vs. FreeStyle Libre 14-day


AUG-11, 2021; KNOW LABS R&D LABORATORY






Bio-RFID vs. Dexcom G6

AUG-11, 2021; KNOW LABS R&D LABORATORY



Bio-RFID Expected Path-to-Market



Why Know Labs?



Global Innovator	IP Portfolio	Medical Device	Proven to Work	100+ Potential Applications
<ul style="list-style-type: none">• Bio-RFID distinctive approach to glucose detection• Combination of radio and microwave spectroscopy	<ul style="list-style-type: none">• Nearly 60 patents issued and pending• Foundational patents that cover more than 100 analytes.	<ul style="list-style-type: none">• Highly accurate medical device to serve the needs of hundreds of millions• Many players either focus on wellness or shifted from medical to wellness due to the low accuracy of their devices (MARD > 10%)	<ul style="list-style-type: none">• Hundreds of tests proved that Bio-RFID can measure blood glucose levels non-invasively• High level of accuracy achieved (MARD < 6.7%)	<ul style="list-style-type: none">• Foundational technology platform• Real-world commercialization opportunities across multiple industries



FY2022 Key Initiatives

- | | |
|--------------------------------|---|
| ✓ <u>Capital Markets</u> | - Uplist to a national exchange
- Institutional research coverage |
| ✓ <u>Intellectual Property</u> | - Expand portfolio of patents, trademarks, and trade secrets |
| ✓ <u>Product Development</u> | - KnowU production units
- Bio-RFID sensor miniaturization for UBand |
| ✓ <u>Bio-RFID Validation</u> | - Internal clinical trials
- FDA pre-submission meeting
- FDA large scale clinical trials |
| ✓ <u>Business Operations</u> | - Planned key hires
- Initiate KnowU go-to-market strategy
- Explore strategic/commercial relationships |

THANK YOU

www.knowlabs.co

ask@knowlabs.co

Know Labs, Inc.
OTCQB: KNWN

